ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Argus opinion

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Apr 21, 2022 7:34am

146 Views

Post# 34619292

RE:Argus opinion

Great to see another critical milestone nearing completion.
.
"[PMN is] preparing GLP toxicology and pharmacokinetics (PK) studies in nonhuman primates. ProMIS expects to complete the PK studies during the second quarter of 2022."

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week